文献速递鼻科

由外向内Draf III额窦手术治疗慢性鼻窦炎后患者报告嗅觉改善

Patient-reported olfaction improves following outside-in Draf III frontal sinus surgery for chronic rhinosinusitis.
PubMed 文献 · Laryngoscope · 2018-09-19

术后患者自评嗅觉损失中重度比例从71.2%降至27.6%,SNOT-22评分显著改善,用药依从性与临床结局改善相关,阿司匹林加重性呼吸系统疾病是预后不良的危险因素。

要点

  • 由外向内Draf III术后患者自评嗅觉损失中重度比例由71.2%降至27.6%(P<0.01)。
  • SNOT-22评分术后显著改善(2.32±1.09 vs 0.78±0.69,P<0.0001)。

核心结论

  • 由外向内Draf III额窦手术似可带来包括嗅觉在内的多项患者自报结局的持续且有意义的改善。
  • 需进一步研究并与侵袭性更小的手术比较以确认其真实获益。

研究设计与样本

  • 中位随访时间30.6个月(范围12.2-72.1)。
  • 排除因非炎症性疾病行Draf III者;术后维持长期皮质类固醇冲洗并评估依从性。

主要发现

  • 术前多数患者自评嗅觉损失为中度或更差,术后显著改善(71.2% vs 27.6%;Kendall tau-b,P<0.01)。
  • SNOT-22评分术后改善(2.32±1.09 vs 0.78±0.69,P<0.0001)。
  • 用药依从性与临床结局评分改善显著相关(Kendall tau-b,P<0.004)。

关键数值与推荐

  • 嗅觉损失中重度比例:术前71.2%,术后27.6%(Kendall tau-b,P<0.01)。
  • SNOT-22评分:术前2.32±1.09,术后0.78±0.69(P<0.0001)。
  • 证据等级:Level 4。

临床怎么用

  • 对炎症性慢性鼻窦炎伴嗅觉障碍患者,由外向内Draf III可作为改善自报嗅觉与整体鼻窦结局的手术选择。
  • 术后应强调长期皮质类固醇冲洗的依从性,依从性与临床结局改善相关。
  • 合并阿司匹林加重性呼吸系统疾病者预后可能较差,术前咨询应提及。
  • 该术式真实获益仍需与侵袭性更小的手术进行对照研究确认。

局限性

  • 为回顾性连续病例系列,证据等级为Level 4。
  • 单中心、单一术者经验,结果外推受限。
  • 缺乏与侵袭性更小手术的对照组。
  • 嗅觉等结局为患者自报指标,未报告客观嗅觉测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Draf III frontal sinusotomy is an established surgical procedure with an important role in the surgical management of recalcitrant chronic rhinosinusitis (CRS). In 2012, the outside-in approach to the Draf III was described as a safe and efficient procedure. Smell recovery in inflammatory CRS is challenging, and to date there is limited evidence suggesting that Draf III improves patient-reported olfactory dysfunction from CRS. METHODS: A consecutive series of patients who underwent an outside-in Draf III for inflammatory CRS by a single, tertiary rhinologist were reviewed. Patients were excluded if the Draf III was performed for noninflammatory conditions. Postoperatively, patients were maintained on long-term corticosteroid irrigations, and adherence was assessed. Prospectively collected data included patient demographics, a visual analogue scale for smell, overall Sinonasal Outcome Test Score (SNOT-22), global nasal function score, and a clinician-graded clinical outcome score. RESULTS: One hundred and four patients (41.1% female) aged 54 ± 12 years underwent an outside-in Draf III. The median follow-up time was 30.6 months (range 12.2-72.1). The majority of patients rated their smell loss as moderate or worse preoperatively; however, this was significantly improved at postoperative review (71.2% vs. 27.6%; Kendall tau-b, P < 0.01). The SNOT-22 score improved after surgery (2.32 ± 1.09 vs. 0.78 ± 0.69, P < 0.0001). Medication adherence was significantly associated with improved clinical outcome score (Kendall tau-b, P < 0.004). Aspirin exacerbated respiratory disease was found to be a significant risk factor predicting poor clinical outcome on univariate analysis (Odds Ratio = 4.69 (1.03-21.2), P = 0.04). CONCLUSION: The outside-in Draf III appears to facilitate sustained, meaningful improvement in several self-reported outcomes, including smell. However, further study and comparison to less aggressive surgery will be required to confirm its true benefit. LEVEL OF EVIDENCE: Level 4 Laryngoscope, 129:25-30, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Wong EH, Do TQ, Harvey RJ, et al. Patient-reported olfaction improves following outside-in Draf III frontal sinus surgery for chronic rhinosinusitis. Laryngoscope. 2018. PMID: 30229923. doi:10.1002/lary.27352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。